Rigel Pharmaceuticals (RIGL) PT Raised to $11 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Rigel Pharmaceuticals (RIGL) PT Raised to $8 at H.C. Wainwright
January 23, 2019 11:09 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $8.00 (from $7.50) while maintaining a Buy rating.
... MorePre-Open Stock Movers 01/23: (ATHX) (SYF) (RIGL) Higher; (BLPH) (TSE) (PTCT) Lower (more...)
January 23, 2019 9:30 AM ESTToday's Pre-Open Movers
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 25% LOWER; announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions.
Athersys, Inc. (NASDAQ: ATHX) 20.1% HIGHER; announced today... More
UPDATE: Rigel Pharma (RIGL) Reports Collaboration and License Agreement with Grifols S.A. (GRFS) to Commercialize Fostamatinib Disodium Hexahydrate in Europe and Turkey
January 23, 2019 7:35 AM EST(Updated - January 23, 2019 7:36 AM EST)
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols, S.A (NASDAQ: GRFS) to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey. Grifols is a global healthcare company and a leading producer of plasma-derived medicines for the treatment of rare and chronic diseases, including intravenous immunoglobulin (IVIG) which is used in the treatment of ITP and AIHA. Fostamatinib is commercially available in the U.S.... More
